The global antibiotic drugs market was valued at US$ 43.6 billion in 2022 and is expected to reach US$ 64.9 billion by 2033. The sales of antibiotic drugs are set to gain traction over the forecast years with a CAGR of around 3.7%.
| Attributes | Key Statistics |
|---|---|
| Market Value (2022) | US$ 43.6 billion |
| Market Value (2023) | US$ 45.0 billion |
| Market Value (2033) | US$ 64.9 billion |
| Estimated Growth (2023 to 2033) | 3.7 % CAGR |
| Share of Top 5 Countries | 66.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Emergence of Infectious Diseases
Expansion in Product Portfolio
The antibiotic drugs market exhibited a CAGR of 2.9% between 2017 and 2022. In 2022, the global market for anti-infective medicines accounted for around US$ 76.7 billion, of which antibiotics have a share of US$ 43.6 billion.
| Attributes | Key Statistics |
|---|---|
| Market Value (2021) | US$ 42.3 billion |
| Estimated Growth (2017 to 2022) | 2.90 % CAGR |
The rising antibiotic treatment for bacterial infections to prevent them from spreading has spurred the global demand for antibiotics. In India, the percentage of single antibiotics consumption is around 4.1 billion, according to the National Library of Medicine. The WHO report on antibiotic usage surveillance, published in 2018, examined data from 65 countries. As determined by daily dosages per 1,000 inhabitants with a rate of 64.4, Mongolia had the most prominent consumption. At 4.4, Burundi received the lowest score. The most popular antibiotics consumed were amoxicillin and amoxicillin/clavulanic acid.
Principal Consultant
New entity development is more time- and money-consuming; it can take a substantial financial burden and several years to complete. Therefore, it is anticipated that the market for antibiotics can be hampered by the high cost of medication research and the rigorous regulatory approval process.
Adverse effects might result from inadequate knowledge of antibiotic administration and the indiscriminate use of antibiotics for minor infections. As a result, it is anticipated that the growing demand for antibiotics will be hampered by the increased side effects brought on by the emergence of resistance and other adverse side effects. For instance, taking a quinolone antibiotic and a systemic corticosteroid may cause tendon injury.
Antibiotic-resistant microorganisms have emerged due to improper antibiotic use and misuse. Antibiotics' potential danger goes beyond the development of antimicrobial resistance, and excessive use of them is linked to adverse consequences on patients, which are particularly obvious in critically ill patients in intensive care units.
Antibiotics are frequently administered to treat illnesses or symptoms that don't react to them or are likely to go away on their own. Additionally, inappropriate or inadequate antibiotics are administered for some bacterial illnesses. Therefore, these factors contribute to the restraint of the growth of the antibiotic drugs market.
| Top Countries | CAGR |
|---|---|
| United States | 12.1% |
| China | 8.2% |
| India | 6.1% |
| United Kingdom | 4.3% |
| Germany | 3.1% |
The United States is dominating the antibiotic drugs market with a share of 12.1%. The market was valued at US$ 5.1 billion in 2022.
The American healthcare system is renowned for its high costs and sophisticated infrastructure. The United States government and regulatory authorities are implementing a variety of cost-effective healthcare schemes to curb catheter-associated UTIs and other infectious diseases. Furthermore, there is a growing need for antibiotics as a result of the increased occurrence of ventilator-associated infections.
According to the Centers for Disease Control and Prevention (CDC), more than 2.8 billion antimicrobial-resistant illnesses occur in the United States each year, resulting in more than 35,000 deaths. The United States government is undertaking several preventative and infection control strategies to reduce the number of illnesses and fatalities caused by antibiotic-resistant bacteria. The United States market for antibiotics is now experiencing significant growth opportunities.
China is an emerging antibiotic drug market with a market share of 8.2%, with a valuation of US$ 3.4 billion in 2022.
The pharmaceutical market in China is the second-leading in the world and is further expanding rapidly. China's OTC pharmaceutical business is still enticing, with a sizable market share. According to OEC (Observatory of Economic Complexity), China was the world's top supplier of antibiotics in 2020, with shipments amounting to US$ 3.98 billion.
The healthcare industry in China has expanded significantly, allowing it to transition from a base for the production of pharmaceuticals to a vital research and development center. As a result, China has strengthened its position as a strategic player in the global pharmaceutical industry, acting as a foundation for increasing research and development while also functioning as a consumer nation. With all these factors combined, the market of antibiotic drugs in China is one of the emerging and lucrative markets.
India is an emerging market and accounted for a market share of more than 6.1% in 2022.
In recent years, small and leading biopharmaceutical businesses in India have relied on the contract research organization (CRO) industry to supply research services to their R&D operations. However, as the majority of medicines in the pipeline are predicted to reach the end stage and be commercialized by the end of the decade, it is anticipated that the need for antibiotics will rise.
Due to the existence of multiple government-funded medical and pharmaceutical institutions with state-of-the-art equipment, clinical trials and research are now a significant industry in India. For multi-centered clinical studies, these facilities are appropriate. These factors are making India one of the new emerging antibiotic drug markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Penicillin-based products dominate the market for antibiotics worldwide. The penicillin antibiotics segment is anticipated to rule the worldwide antibiotics market throughout the forecast period.
| Top Product Type | Penicillins |
|---|---|
| CAGR | 3.6% |
The acceptance of penicillin as a first-line antibiotic therapy and the rising demand for antibiotics to treat various bacterial infections are expected to increase the need for penicillin globally.
People typically contract an infection by contacting infected individuals, eating or drinking contaminated food or water (sometimes called food poisoning), or handling contaminated objects like cutlery, taps, toys, etc.
| Top Indication | Gastrointestinal Infections |
|---|---|
| CAGR | 3.5% |
This results in an increased prevalence of gastrointestinal infection or gastroenteritis. Hence, it had a market share of 26.0% in 2022.
The parenteral route of drug administration occupied 68.6% of global market share in 2022. Intravenous (IV), intramuscular (IM), and subcutaneous parenteral methods are the most significant and often utilized parenteral routes (SC).
| Top Route of Administration | Parenteral |
|---|---|
| CAGR | 3.5% |
For medications with limited GIT absorption and medicines like insulin that are unstable in the GIT, the parenteral route of drug administration is the preferred method.
To expand their product offerings and boost the competitiveness of their companies, the key market participants focus on introducing several effective medications and winning regulatory body clearance. Additionally, businesses are increasingly focusing on expanding their business globally by setting up new labs and facilities to enhance their market presence.
Recent Development
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; the Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, South Africa, North Africa, and GCC Countries. |
| Key Segments Covered | Drug Class, Indication, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Abbott Laboratories; AbbVie; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Merck & Co. Inc.; Mylan N.V.; Novartis International AG (Sandoz); Sanofi; Teva Pharmaceutical Industries Ltd.; Melinta Therapeutics; Pfizer Inc; Basilea Pharmaceutica Ltd.; Tetraphase Pharmaceuticals; Paratek Pharmaceuticals, Inc.; Nabriva Therapeutics plc; Spero Therapeutics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market is likely to be worth US$ 45 billion in 2023.
The market is expected to reach US$ 64.9 billion by 2033.
North America holds 23.9% of the global market in 2022, with the United States being the leading contributor.
China's market is offering lucrative growth, with a market share of 8.2% in 2022.
The United States, China, India, the United Kingdom, and Germany are the top 5 countries.
From 2017 to 2022, the market for antibiotic drugs expanded at the rate of 2.9%.
Pfizer, Sanofi SA, AbbVie Inc. (Allergan plc), Teva Pharmaceuticals, GlaxoSmithKline plc, Novartis AG, Abbott Laboratories, etc.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Brand Mapping Analysis
3.1. Price v/s Drug Class
3.2. Value for Money
3.3. Top of Mind Antibiotics Brands
3.4. Brand Portfolio-by Key Players
3.5. Brand Loyalty Mapping
3.6. Route of Administration Pattern Overview
3.7. Branded vs Unbranded-Market Mix
4. Distribution Channel Wise Key Brand Positioning
4.1. Global Top Retailers and their Brand Offerings
4.1.1. Retail Pharmacies
4.1.2. Hospital Pharmacies
4.1.3. Online Pharmacies
4.2. Retail Pricing Strategies
5. Consumer Buying Behavior Analysis
5.1. Functionality and Drug Demand
5.1.1. Penicillins
5.1.2. Fluoroquinolones
5.1.3. Cephalosporins
5.1.4. Macrolides
5.1.5. Others
5.2. What factors do you consider when deciding to purchase antibiotics?
5.3. How important are product certifications when choosing antibiotics?
5.4. How important is the brand reputation and recognition when selecting antibiotics?
5.5. What marketing channels do you prefer for learning about new antibiotics?
5.6. How often do you purchase new antibiotics?
5.6.1. Once or More Every Month
5.6.2. Once Every 2 months
5.6.3. Once Every 6 Months
5.6.4. Once a Year
5.7. Less Than Once A Year
6. Key Market Trends
6.1. Key Trends Impacting the Market
6.2. Drug class Innovation / Development Trends
7. Key Success Factors
7.1. Disease Epidemiology
7.2. Recent Product Launches
7.3. Regulatory Scenario
7.4. Product Adoption Analysis
7.5. Patient Treatment Journey
7.6. PESTLE Analysis
7.7. Porters Analysis
7.8. Key Promotional Strategies by Key Manufacturers
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Healthcare Spending Outlook
8.1.3. Global Anti-Infective Drugs Market Outlook
8.2. Forecast Factors - Relevance & Impact
8.2.1. Increasing Cases of Allergic Reactions
8.2.2. Rising Adoption of Anti-pyretic
8.2.3. Increase in Research and Development spending
8.2.4. Increase Drug Discovery activity
8.2.5. Approval of New Drug class
8.2.6. Strategical Mergers and Acquisitions Among Key Players
8.3. Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.3.3. Opportunity Analysis
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug class
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million), By Drug class, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Drug class, 2023 to 2033
10.3.1. Penicillins
10.3.2. Fluoroquinolones
10.3.3. Cephalosporins
10.3.4. Macrolides
10.3.5. Others
10.4. Market Attractiveness Analysis By Drug class
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million), By Indication, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Indication, 2023 to 2033
11.3.1. Dermatological Infections
11.3.2. Respiratory Infections
11.3.3. Urinary Tract Infections
11.3.4. Ear Infections
11.3.5. Gastrointestinal Infections
11.3.6. Others
11.4. Market Attractiveness Analysis, By Indication
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million), By Route of Administration, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Route of Administration, 2023 to 2033
12.3.1. Oral
12.3.2. Parenteral
12.4. Market Attractiveness Analysis, By Route of Administration
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million), By Distribution Channel, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Forecast By Distribution Channel, 2023 to 2033
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Online pharmacies
13.4. Market Attractiveness Analysis By Distribution Channel
14. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Forecast By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Drug class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug class
15.4.3. By Indication
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. USA Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug class
15.8.1.2.2. By Indication
15.8.1.2.3. By Route of Administration
15.8.1.2.4. By Distribution Channel
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug class
15.8.2.2.2. By Indication
15.8.2.2.3. By Route of Administration
15.8.2.2.4. By Distribution Channel
16. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Drug class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug class
16.4.3. By Indication
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Mexico Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug class
16.8.1.2.2. By Indication
16.8.1.2.3. By Route of Administration
16.8.1.2.4. By Distribution Channel
16.8.2. Brazil Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug class
16.8.2.2.2. By Indication
16.8.2.2.3. By Route of Administration
16.8.2.2.4. By Distribution Channel
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug class
16.8.3.2.2. By Indication
16.8.3.2.3. By Route of Administration
16.8.3.2.4. By Distribution Channel
17. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. UK
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Drug class
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug class
17.4.3. By Indication
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug class
17.8.1.2.2. By Indication
17.8.1.2.3. By Route of Administration
17.8.1.2.4. By Distribution Channel
17.8.2. Italy Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug class
17.8.2.2.2. By Indication
17.8.2.2.3. By Route of Administration
17.8.2.2.4. By Distribution Channel
17.8.3. France Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug class
17.8.3.2.2. By Indication
17.8.3.2.3. By Route of Administration
17.8.3.2.4. By Distribution Channel
17.8.4. UK Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug class
17.8.4.2.2. By Indication
17.8.4.2.3. By Route of Administration
17.8.4.2.4. By Distribution Channel
17.8.5. Spain Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Drug class
17.8.5.2.2. By Indication
17.8.5.2.3. By Route of Administration
17.8.5.2.4. By Distribution Channel
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Drug class
17.8.6.2.2. By Indication
17.8.6.2.3. By Route of Administration
17.8.6.2.4. By Distribution Channel
17.8.7. Nordic Countries Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Drug class
17.8.7.2.2. By Indication
17.8.7.2.3. By Route of Administration
17.8.7.2.4. By Distribution Channel
17.8.8. Russia Market Analysis
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast by Market Taxonomy
17.8.8.2.1. By Drug class
17.8.8.2.2. By Indication
17.8.8.2.3. By Route of Administration
17.8.8.2.4. By Distribution Channel
18. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Drug class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug class
18.4.3. By Indication
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. China Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug class
18.8.1.2.2. By Indication
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Distribution Channel
18.8.2. Japan Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug class
18.8.2.2.2. By Indication
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Distribution Channel
18.8.3. South Korea Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Drug class
18.8.3.2.2. By Indication
18.8.3.2.3. By Route of Administration
18.8.3.2.4. By Distribution Channel
19. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Drug class
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug class
19.4.3. By Indication
19.4.4. By Route of Administration
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. India Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug class
19.8.1.2.2. By Indication
19.8.1.2.3. By Route of Administration
19.8.1.2.4. By Distribution Channel
19.8.2. Indonesia Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug class
19.8.2.2.2. By Indication
19.8.2.2.3. By Route of Administration
19.8.2.2.4. By Distribution Channel
19.8.3. Malaysia Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug class
19.8.3.2.2. By Indication
19.8.3.2.3. By Route of Administration
19.8.3.2.4. By Distribution Channel
19.8.4. Thailand Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug class
19.8.4.2.2. By Indication
19.8.4.2.3. By Route of Administration
19.8.4.2.4. By Distribution Channel
20. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Drug class
20.3.3. By Indication
20.3.4. By Route of Administration
20.3.5. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Drug class
20.4.3. By Indication
20.4.4. By Route of Administration
20.4.5. By Distribution Channel
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Drug class
20.8.1.2.2. By Indication
20.8.1.2.3. By Route of Administration
20.8.1.2.4. By Distribution Channel
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Drug class
20.8.2.2.2. By Indication
20.8.2.2.3. By Route of Administration
20.8.2.2.4. By Distribution Channel
21. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. South Africa
21.3.1.4. North Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Drug class
21.3.3. By Indication
21.3.4. By Route of Administration
21.3.5. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Drug class
21.4.3. By Indication
21.4.4. By Route of Administration
21.4.5. By Distribution Channel
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Drug class
21.8.1.2.2. By Indication
21.8.1.2.3. By Route of Administration
21.8.1.2.4. By Distribution Channel
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Drug class
21.8.2.2.2. By Indication
21.8.2.2.3. By Route of Administration
21.8.2.2.4. By Distribution Channel
21.8.3. South Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Drug class
21.8.3.2.2. By Indication
21.8.3.2.3. By Route of Administration
21.8.3.2.4. By Distribution Channel
21.8.4. North Africa Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Drug class
21.8.4.2.2. By Indication
21.8.4.2.3. By Route of Administration
21.8.4.2.4. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Concentration
22.4. Market Presence Analysis
22.4.1. Regional Footprint Analysis
22.4.2. Drug class Footprint Analysis
22.4.3. Channel Footprint Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Abbott Laboratries
23.3.1.1. Overview
23.3.1.2. Drug class Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Key Developments
23.3.1.5. SWOT Analysis
23.3.1.6. Strategy Overview
23.3.1.6.1. Marketing Strategies
23.3.1.6.2. Drug class Strategies
23.3.1.6.3. Channel Strategies
23.3.2. Allergan Plc.,
23.3.2.1. Overview
23.3.2.2. Drug class Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Key Developments
23.3.2.5. SWOT Analysis
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategies
23.3.2.6.2. Drug class Strategies
23.3.2.6.3. Channel Strategies
23.3.3. F. Hoffmann-La Roche Ltd.,
23.3.3.1. Overview
23.3.3.2. Drug class Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Key Developments
23.3.3.5. SWOT Analysis
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategies
23.3.3.6.2. Drug class Strategies
23.3.3.6.3. Channel Strategies
23.3.4. GlaxoSmithKline plc,
23.3.4.1. Overview
23.3.4.2. Drug class Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Key Developments
23.3.4.5. SWOT Analysis
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategies
23.3.4.6.2. Drug class Strategies
23.3.4.6.3. Channel Strategies
23.3.5. Merck & Co. Inc.,
23.3.5.1. Overview
23.3.5.2. Drug class Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Key Developments
23.3.5.5. SWOT Analysis
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategies
23.3.5.6.2. Drug class Strategies
23.3.5.6.3. Channel Strategies
23.3.6. Mylan N.V.,
23.3.6.1. Overview
23.3.6.2. Drug class Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Key Developments
23.3.6.5. SWOT Analysis
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategies
23.3.6.6.2. Drug class Strategies
23.3.6.6.3. Channel Strategies
23.3.7. Novartis International AG (Sandoz),
23.3.7.1. Overview
23.3.7.2. Drug class Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Key Developments
23.3.7.5. SWOT Analysis
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategies
23.3.7.6.2. Drug class Strategies
23.3.7.6.3. Channel Strategies
23.3.8. Pfizer Inc., Sanofi,
23.3.8.1. Overview
23.3.8.2. Drug class Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Key Developments
23.3.8.5. SWOT Analysis
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategies
23.3.8.6.2. Drug class Strategies
23.3.8.6.3. Channel Strategies
23.3.9. Teva Pharmaceutical Industries Ltd.
23.3.9.1. Overview
23.3.9.2. Drug class Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Key Developments
23.3.9.5. SWOT Analysis
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategies
23.3.9.6.2. Drug class Strategies
23.3.9.6.3. Channel Strategies
23.3.10. Melinta Therapeutics
23.3.10.1. Overview
23.3.10.2. Drug class Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Key Developments
23.3.10.5. SWOT Analysis
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategies
23.3.10.6.2. Drug class Strategies
23.3.10.6.3. Channel Strategies
23.3.11. Pfizer Inc,
23.3.11.1. Overview
23.3.11.2. Drug class Portfolio
23.3.11.3. Sales Footprint
23.3.11.4. Key Developments
23.3.11.5. SWOT Analysis
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategies
23.3.11.6.2. Drug class Strategies
23.3.11.6.3. Channel Strategies
23.3.12. Basilea Pharmaceutica Ltd.
23.3.12.1. Overview
23.3.12.2. Drug class Portfolio
23.3.12.3. Sales Footprint
23.3.12.4. Key Developments
23.3.12.5. SWOT Analysis
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategies
23.3.12.6.2. Drug class Strategies
23.3.12.6.3. Channel Strategies
23.3.13. Tetraphase Pharmaceuticals
23.3.13.1. Overview
23.3.13.2. Drug class Portfolio
23.3.13.3. Sales Footprint
23.3.13.4. Key Developments
23.3.13.5. SWOT Analysis
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategies
23.3.13.6.2. Drug class Strategies
23.3.13.6.3. Channel Strategies
23.3.14. Paratek Pharmaceuticals, Inc.
23.3.14.1. Overview
23.3.14.2. Drug class Portfolio
23.3.14.3. Sales Footprint
23.3.14.4. Key Developments
23.3.14.5. SWOT Analysis
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategies
23.3.14.6.2. Drug class Strategies
23.3.14.6.3. Channel Strategies
23.3.15. Nabriva Therapeutics plc
23.3.15.1. Overview
23.3.15.2. Drug class Portfolio
23.3.15.3. Sales Footprint
23.3.15.4. Key Developments
23.3.15.5. SWOT Analysis
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategies
23.3.15.6.2. Drug class Strategies
23.3.15.6.3. Channel Strategies
23.3.16. Spero Therapeutics
23.3.16.1. Overview
23.3.16.2. Drug class Portfolio
23.3.16.3. Sales Footprint
23.3.16.4. Key Developments
23.3.16.5. SWOT Analysis
23.3.16.6. Strategy Overview
23.3.16.6.1. Marketing Strategies
23.3.16.6.2. Drug class Strategies
23.3.16.6.3. Channel Strategies
24. Assumptions and Acronyms Used
25. Research Methodology
Healthcare
June 2023
REP-GB-13025
273 pages
Explore Healthcare Insights
View Reports
Antibiotic Drug Market
